Lipocine Inc. 8-K

What Happened
Lipocine Inc. (LPCN) filed a Form 8‑K on June 12, 2026 (Accession No. 0001493152-26-028429) reporting that the company hosted a virtual key opinion leader (KOL) event the same day. The presentation focused on unmet needs in postpartum depression and the clinical profile of Lipocine’s investigational product LPCN‑1154. The slide deck from the event is furnished as Exhibit 99.1 to the filing and is incorporated by reference; Lipocine also posted a link to the presentation on its corporate website (www.lipocine.com).

Key Details

• Event date: June 12, 2026 — virtual KOL event highlighting postpartum depression and LPCN‑1154.
• Presentation: Furnished as Exhibit 99.1 to the Form 8‑K and incorporated by reference.
• Accessibility: A link to the presentation is available on Lipocine’s corporate website.
• Filing: Reported under Item 8.01 (Other Events) of the Form 8‑K.

Why It Matters
For investors, this filing documents Lipocine’s clinical and scientific outreach around LPCN‑1154 and its potential role in treating postpartum depression. While the 8‑K does not report new clinical trial results, regulatory actions, or financial metrics, making the KOL presentation public can increase transparency about the drug’s clinical profile and may affect stakeholder awareness and interest. There are no earnings, executive changes, or deal announcements in this filing.